Reports Q3 revenue $10.32M, consensus $9.69M. “Our strong product revenue growth in the third quarter allowed us to achieve positive GAAP net income from product revenue for the first time in the Company’s history and we’re pleased to reach this important milestone one quarter ahead of our original goal. We are proud of our ability to continue delivering exceptional growth, as demonstrated by our 15th straight quarter of sequential growth in product revenue, while managing the bottom line,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals (ETON).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- ETON Earnings this Week: How Will it Perform?
- Eton Pharmaceuticals awarded second patent for ET-400
- Eton Pharmaceuticals price target raised to $15 from $10 at Craig-Hallum
- Eton Pharmaceuticals price target raised to $11 from $9 at H.C. Wainwright
- Eton Pharmaceuticals price target raised to $10 from $8 at Craig-Hallum